Teva vs. Amneal: Inhaler Dose Counter Patent Dispute Dismissed

Introduction

In a pharmaceutical patent dispute that ran nearly two years before resolving without a judicial ruling on the merits, Teva Branded Pharmaceutical Products R&D LLC and its affiliates filed suit against Amneal Pharmaceuticals and its related entities in October 2023 over six patents covering metered-dose inhaler (MDI) dose counter technology. The case, filed in the District of New Jersey (Case No. 2:23-cv-20964), concluded on July 29, 2025, when both parties jointly agreed to a consent order of dismissal without prejudice — each side bearing its own costs.

For patent attorneys, in-house IP counsel, and R&D professionals operating in the pharmaceutical device space, this inhaler patent infringement case offers important strategic signals. Dismissals without prejudice following nearly two years of litigation often reflect negotiated licensing resolutions, ongoing ANDA or regulatory developments, or shifting commercial calculus — none of which appear on the public docket. Understanding what this outcome may mean for inhaler technology patent strategy requires a careful reading of the procedural record and the patents at issue.

Case Overview

The Parties

The Patents at Issue

Six U.S. patents were asserted, all directed to inhaler dose counter mechanisms:

• • US8,132,712B2 — foundational dose counter architecture for inhalers
• • US9,463,289B2 — structural and assembly innovations for inhaler dose counters
• • US9,808,587B2 — refinements to dose counter design
• • US10,561,808B2 — anti-reverse rotation actuator technology for dose counters
• • US10,695,512B2 — additional inhaler dose counter configurations
• • US11,395,889B2 — most recently issued patent in the portfolio; metered-dose inhaler systems

The Accused Products

The accused products fall into three categories: dose counters for inhalers incorporating anti-reverse rotation actuators, dose counters with specific assembly configurations, and metered-dose inhalers incorporating these technologies. The commercial significance is substantial — dose counters are required by FDA for certain MDI products, making them a critical component of any generic inhaler market entry strategy.

Legal Representation

Plaintiff: Walsh Pizzi O’Reilly Falanga LLP (Christine Clark, Hector Daniel Ruiz, Liza M. Walsh, Selena Miriam Ellis)
Defendant: Stone Conroy LLC (Rebekah R. Conroy, Shalom D. Stone)

Litigation Timeline & Procedural History

The complaint was filed on October 6, 2023, in the District of New Jersey — a jurisdiction with deep familiarity in pharmaceutical patent litigation, particularly Hatch-Waxman and device-related disputes. New Jersey’s established pharmaceutical IP docket makes it a strategically rational venue for Teva, whose principal U.S. operations are headquartered in the region.

The case ran 662 days from filing to dismissal — approximately 22 months. This duration places the litigation well into active discovery and potentially claim construction territory, though no specific milestones such as Markman hearings, summary judgment motions, or trial scheduling orders appear on the public verdict record provided. The absence of a disclosed chief judge assignment is noted; case assignment details are publicly accessible via PACER.

The case closed at the first-instance (district court) level, meaning no appellate proceedings were initiated or concluded. The joint application for a consent dismissal — agreed upon by all named parties across both plaintiff and defendant groups — signals a coordinated resolution rather than a unilateral withdrawal.

The Verdict & Legal Analysis

Outcome

On July 29, 2025, the District of New Jersey entered a Consent Order of Dismissal without prejudice in Teva Branded Pharmaceutical Products R&D LLC et al. v. Amneal Pharmaceuticals, Inc. et al. All claims, defenses, and counterclaims were dismissed. No damages were awarded. No injunctive relief was granted. Each party bore its own legal costs.

The dismissal was without prejudice, meaning Teva retains the right to refile claims based on the same patents should circumstances warrant — a legally significant distinction from a with-prejudice dismissal, which would bar refiling.

Verdict Cause Analysis

The case was styled as an infringement action. No judicial findings on patent validity, claim construction, or infringement were issued. The consent dismissal forecloses any precedential ruling on the six asserted patents’ scope or enforceability.

The structure of the defendant group is notable: Amneal entities spanning New York, Ireland, and the U.S. parent were all named, suggesting Teva sought broad jurisdictional coverage — a litigation posture consistent with global generic pharmaceutical manufacturers whose supply chains cross multiple entities and jurisdictions.

The involvement of Amneal Ireland Limited alongside a U.S. parent and LLC structure suggests potential cross-border manufacturing or supply chain considerations that may have influenced both the litigation strategy and the ultimate resolution pathway.

Legal Significance

Because the dismissal was without prejudice and by consent, this case establishes no claim construction precedent for the six asserted patents. Patent attorneys should note that all six patents remain enforceable and unrestricted by any judicial ruling. Any future assertion by Teva based on these patents begins on a clean procedural slate.

For the broader inhaler dose counter patent landscape, the case demonstrates that multi-patent portfolio assertions in pharmaceutical device litigation frequently resolve outside of judicial merits determination — a pattern consistent with Hatch-Waxman litigation dynamics where business and regulatory factors often supersede litigation timelines.

Strategic Takeaways

For Patent Holders:
Teva’s six-patent assertion across a layered prosecution portfolio illustrates the value of building depth in device technology IP. Even without a favorable judgment, the 662-day litigation cycle may have served commercial deterrence or negotiation leverage purposes.

For Accused Infringers:
Amneal’s retention of specialized pharmaceutical IP counsel (Stone Conroy LLC) and the ultimate consent dismissal reflects a defense strategy focused on resolution efficiency. Generic manufacturers should evaluate whether litigation cost trajectories favor early resolution over protracted claim construction battles.

For R&D Teams:
The anti-reverse rotation actuator technology (US10,561,808B2) and assembly methodology patents (US9,463,289B2) represent specific design constraints that inhaler device engineers should evaluate during freedom-to-operate (FTO) analysis. These patents remain active and fully enforceable.

FAQ

What patents were involved in Teva v. Amneal (2:23-cv-20964)?

Six U.S. patents covering inhaler dose counter technology: US8,132,712B2; US9,463,289B2; US9,808,587B2; US10,561,808B2; US10,695,512B2; and US11,395,889B2.

Why was the case dismissed without prejudice?

Both parties jointly applied for the consent dismissal. No reason was stated publicly. Without-prejudice dismissal preserves Teva’s right to refile and is consistent with negotiated resolution.

How does this affect inhaler patent litigation broadly?

The case reinforces that branded pharmaceutical companies actively assert device patents as secondary IP lines. Generic inhaler developers face multi-patent enforcement risk beyond drug formulation IP.